VICTORIA FAUCHEUX: Open Payments
NPI 1194261008 · COVINGTON, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,650 in 69 payments from 34 companies in 2025. Trend: 2023 $0 · 2024 $766 · 2025 $1,650
Food & beverage: $1,650
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 4 | $182 |
| Genentech USA, Inc. | 7 | $147 |
| Janssen Biotech, Inc. | 9 | $143 |
| Novo Nordisk Inc | 1 | $125 |
| Stemline Therapeutics Inc. | 5 | $87 |
| Novartis Pharmaceuticals Corporation | 4 | $76 |
| Adaptive Biotechnologies Corporation | 3 | $74 |
| Incyte Corporation | 3 | $67 |
| PharmaEssentia USA Corporation | 2 | $60 |
| JAZZ PHARMACEUTICALS INC. | 2 | $55 |
Products named: Ozempic, RYBREVANT, Itovebi, Orserdu, clonoSEQ, BESREMI, ZIIHERA, Fabhalta.
Industry payments across LA — which companies pay providers there.
